Clinical oncology panels
GALEAS™ Bladder
A comprehensive biomarker test delivering cystoscopy-level accuracy for all grades and stages of bladder cancer from a simple urine sample.
With sensitivity of >90%, GALEAS Bladder offers a non-invasive, sample-to-report, molecular triage for hematuria patients, allowing urologists to make informed decisions as to whether further investigation is required.
GALEAS™ Tumor
A clinically validated panel designed in parallel with variant calling software for comprehensive genomic profiling of solid tumors.
GALEAS Tumor profiles key DNA biomarkers across 519 genes streamlining the detection of SNVs, INDELs, CNVs, TMB and MSI into a single workflow. Cloud-based bioinformatic pipelines enable rapid integration into any laboratory.
GALEAS™ HereditaryPlus
A comprehensive hereditary cancer test with tailored bioinformatics offering a viable option for reducing MLPA.
An expertly curated NGS panel design with coverage of 146 genes with known associations in inherited cancer, GALEAS HereditaryPlus offers full coverage of the UK National Genomics Test Directory and compliant with ESMO/AMP guidelines.
GALEAS™ uPCR: ESR1
An ultrasensitive qPCR assay designed to detect eleven of the most prevalent actionable ESR1 variants with high sensitivity and specificity in cell-free DNA.
Simple to use and requiring only standard qPCR cyclers, this assay can be deployed in almost any molecular laboratory.
Custom panels
Custom Oncology Panels
Customize your NGS oncology panel with the ultra-sensitive Cell3™ Target enrichment system. Convert cfDNA, gDNA, or FFPE DNA into libraries for next-generation sequencing.
Our error suppression technology enables confident mutation calling down to 0.1% VAF and is ideal for rare variant detection in liquid and tissue biopsies.
